Aethlon Medical annual free cash flow
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Aethlon Medical Free Cash Flow (FCF) History (AEMD)
Aethlon Medical reported −$7.0M in free cash flow for fiscal 2026, an increase of $643,436 from the previous fiscal year.
View full Aethlon Medical company overviewAethlon Medical free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2026 | 2026-03-31 | −$7.0M | $643,436 | — | — |
| 2025 | 2025-03-31 | −$7.6M | $2.7M | — | — |
| 2024 | 2024-03-31 | −$10.4M | $1.1M | — | — |
| 2023 | 2023-03-31 | −$11.4M | −$1.3M | — | −1993.62% |
| 2022 | 2022-03-31 | −$10.1M | −$3.3M | — | −3439.01% |
| 2021 | 2021-03-31 | −$6.8M | −$1.5M | — | −1035.47% |
| 2020 | 2020-03-31 | −$5.3M | −$1.1M | — | −822.73% |
| 2019 | 2019-03-31 | −$4.3M | −$357,930 | — | −1869.76% |
| 2018 | 2018-03-31 | −$3.9M | −$413,170 | — | −2630.24% |
| 2017 | 2017-03-31 | −$3.5M | $816,281 | — | −898.39% |
| 2016 | 2016-03-31 | −$4.3M | $710,800 | — | −489.37% |
| 2015 | 2015-03-31 | −$5.0M | −$2.8M | — | −662.29% |
| 2014 | 2014-03-31 | −$2.2M | −$136,170 | — | −137.64% |
| 2013 | 2013-03-31 | −$2.1M | −$255,767 | — | −170.64% |
| 2012 | 2012-03-31 | −$1.8M | $127,784 | — | −135.56% |
| 2011 | 2011-03-31 | −$2.0M | — | — | — |
Aethlon Medical quarterly free cash flow
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q3.13
Q3.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q4.26
Q1.27
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q1 2027 | 2026-06-30 | −$1.9M | −$190,752 | — | — |
| Q4 2026 | 2026-03-31 | −$1.8M | −$77,591 | — | — |
| Q1 2026 | 2025-06-30 | −$1.7M | $32,600 | — | — |
| Q4 2025 | 2025-03-31 | −$1.7M | $895,508 | — | — |
| Q3 2025 | 2024-12-31 | −$2.0M | $373,662 | — | — |
| Q2 2025 | 2024-09-30 | −$2.2M | $496,358 | — | — |
| Q1 2025 | 2024-06-30 | −$1.7M | $965,233 | — | — |
| Q4 2024 | 2024-03-31 | −$2.6M | $387,656 | — | — |
| Q3 2024 | 2023-12-31 | −$2.4M | −$284,042 | — | — |
| Q2 2024 | 2023-09-30 | −$2.7M | $906,630 | — | — |
| Q1 2024 | 2023-06-30 | −$2.7M | $57,316 | — | — |
| Q4 2023 | 2023-03-31 | −$3.0M | $353,471 | — | −515.11% |
| Q3 2023 | 2022-12-31 | −$2.1M | $673,452 | — | — |
| Q2 2023 | 2022-09-30 | −$3.6M | −$1.7M | — | — |
| Q1 2023 | 2022-06-30 | −$2.8M | −$659,884 | — | — |
| Q4 2022 | 2022-03-31 | −$3.3M | −$1.1M | — | −25247.61% |
| Q3 2022 | 2021-12-31 | −$2.8M | −$547,151 | — | −16218.10% |
| Q2 2022 | 2021-09-30 | −$1.9M | −$686,364 | — | −1453.87% |
| Q1 2022 | 2021-06-30 | −$2.1M | −$990,420 | — | −1599.05% |
| Q4 2021 | 2021-03-31 | −$2.2M | −$619,926 | — | −6554.73% |
| Q3 2021 | 2020-12-31 | −$2.2M | −$944,431 | — | −356.70% |
| Q2 2021 | 2020-09-30 | −$1.2M | −$39,980 | — | — |
| Q1 2021 | 2020-06-30 | −$1.1M | $128,789 | — | — |
| Q4 2020 | 2020-03-31 | −$1.6M | −$226,483 | — | −785.55% |
| Q3 2020 | 2019-12-31 | −$1.3M | −$198,206 | — | −310.67% |
| Q2 2020 | 2019-09-30 | −$1.2M | −$201,011 | — | — |
| Q1 2020 | 2019-06-30 | −$1.2M | −$430,140 | — | −4161.90% |
| Q4 2019 | 2019-03-31 | −$1.4M | −$378,426 | — | −1746.84% |
| Q3 2019 | 2018-12-31 | −$1.1M | −$296,590 | — | — |
| Q2 2019 | 2018-09-30 | −$991,265 | $37,248 | — | — |
| Q1 2019 | 2018-06-30 | −$818,431 | $279,838 | — | −546.99% |
| Q4 2018 | 2018-03-31 | −$1.0M | −$51,609 | — | −1362.14% |
| Q3 2018 | 2017-12-31 | −$789,674 | −$1,433 | — | −1055.53% |
| Q2 2018 | 2017-09-30 | −$1.0M | −$91,337 | — | — |
| Q1 2018 | 2017-06-30 | −$1.1M | −$268,791 | — | — |
| Q4 2017 | 2017-03-31 | −$967,438 | $159,722 | — | — |
| Q3 2017 | 2016-12-31 | −$788,241 | $184,985 | — | — |
| Q2 2017 | 2016-09-30 | −$937,176 | $503,046 | — | −241.89% |
| Q1 2017 | 2016-06-30 | −$829,478 | −$31,472 | — | −17895.97% |
| Q4 2016 | 2016-03-31 | −$1.1M | $770,477 | — | −550.73% |
| Q3 2016 | 2015-12-31 | −$973,226 | $784,185 | — | −323.30% |
| Q2 2016 | 2015-09-30 | −$1.4M | −$809,605 | — | −764.59% |
| Q1 2016 | 2015-06-30 | −$798,006 | −$34,257 | — | −414.53% |
| Q4 2015 | 2015-03-31 | −$1.9M | — | — | −955.45% |
| Q3 2015 | 2014-12-31 | −$1.8M | −$856,566 | — | −5256.36% |
| Q2 2015 | 2014-09-30 | −$630,617 | — | — | −131.63% |
| Q1 2015 | 2014-06-30 | −$763,749 | — | — | −1488.91% |
| Q3 2014 | 2013-12-31 | −$900,845 | −$239,068 | — | −1180.46% |
| Q3 2013 | 2012-12-31 | −$661,777 | −$596,737 | — | −316.97% |
| Q4 2012 | 2012-03-31 | −$740,269 | −$284,900 | — | — |
| Q3 2012 | 2011-12-31 | −$65,040 | $486,341 | — | −6.79% |
| Q2 2012 | 2011-09-30 | −$495,494 | $105,673 | — | — |
| Q1 2012 | 2011-06-30 | −$542,287 | −$179,330 | — | — |
| Q4 2011 | 2011-03-31 | −$455,369 | — | — | — |
| Q3 2011 | 2010-12-31 | −$551,381 | — | — | — |
| Q2 2011 | 2010-09-30 | −$601,167 | — | — | — |
| Q1 2011 | 2010-06-30 | −$362,957 | — | — | — |
Aethlon Medical free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$6.8M to −$7.0M, a net decrease of $177,275. Aethlon Medical's latest reported quarter, Q1 2027, generated −$1.9M in free cash flow, a decrease of $190,752 year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Aethlon Medical source filings ↗Community posts
Aethlon agrees to North Immunology merger backed by $180 million financing
Aethlon ($AEMD) Medical agreed to an all-stock merger with North Immunology, accompanied by a private placement described as approximately $180 million in gross proceeds. That amount includes the conversion of roughly $34 million of existin ...
